Compare CHD & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHD | UTHR |
|---|---|---|
| Founded | 1846 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4B | 25.1B |
| IPO Year | 2014 | 1999 |
| Metric | CHD | UTHR |
|---|---|---|
| Price | $99.07 | $559.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 14 |
| Target Price | $102.18 | ★ $567.57 |
| AVG Volume (30 Days) | ★ 1.7M | 478.3K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.28% | N/A |
| EPS Growth | ★ 27.43 | 13.07 |
| EPS | 0.91 | ★ 5.82 |
| Revenue | ★ $6,203,200,000.00 | $1,483,300,000.00 |
| Revenue This Year | $0.25 | $6.39 |
| Revenue Next Year | $3.65 | $14.18 |
| P/E Ratio | $108.78 | ★ $96.76 |
| Revenue Growth | 1.57 | ★ 2.38 |
| 52 Week Low | $81.33 | $272.18 |
| 52 Week High | $106.04 | $609.35 |
| Indicator | CHD | UTHR |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 56.23 |
| Support Level | $91.85 | $533.78 |
| Resistance Level | $100.48 | $580.39 |
| Average True Range (ATR) | 2.17 | 12.44 |
| MACD | 0.07 | 2.14 |
| Stochastic Oscillator | 78.83 | 94.83 |
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.